biostudies-literatureChoi KHPatient-centered Clinical Research Coordinating Center funded by the Ministry of Health &amp; Welfare, Republic of Koreae086971https://www.ebi.ac.uk/biostudies/studies/S-EPMC11367310biostudies-literatureUnknown14(8)<h4>Introduction</h4>There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction.<h4>Methods and analysis</h4>The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejectionBMJ openDiscontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial.PMC11367310HC20C0161Her SHHahn JYYu CWSMART-DECISION investigatorsKim JJeong JOPark KTYoon CHYang JHPark YHCho JHCho JKang DJang WJoo SJSuh JSong YBHwang JYAhn SGLee JMKim SMKim HKGuallar EShin ESCho BRPark JPKim BJLim SHChoi SHDoh JHKim WGwon HCNam CWChoi KHLee SRPark TKfalseDiscontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial.<h4>Introduction</h4>There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction.<h4>Methods and analysis</h4>The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection2024-01-01T00:00:00Z2024 Aug2026-07-15T08:07:22.984Z2026-07-02T03:08:55.697ZS-EPMC113673103964527010.1136/bmjopen-2024-086971